Tiger X Medical Inc Stock Other OTC
Equities
US88677A1043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 27 | Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024 | |
Mar. 27 | BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 700K | Sales 2025 * | 700K | Capitalization | 10.1M |
---|---|---|---|---|---|
Net income 2024 * | -15M | Net income 2025 * | -19M | EV / Sales 2024 * | 14.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.4 x |
P/E ratio 2024 * |
-0.9
x | P/E ratio 2025 * |
-0.77
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.16% |
Latest transcript on Tiger X Medical Inc
Managers | Title | Age | Since |
---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 01-12-31 |
David McClung
DFI | Director of Finance/CFO | 61 | 13-08-31 |
Chief Tech/Sci/R&D Officer | - | 17-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 01-12-31 |
Jay Moyes
BRD | Director/Board Member | 70 | 10-12-31 |
Richard Krasno
BRD | Director/Board Member | 82 | 16-10-23 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |